Evolving medical therapies for ulcerative colitis |
| |
Authors: | Phillip Y Chung MD Russell D Cohen MD |
| |
Institution: | (1) Department of Medicine, Section of Gastroenterology, The University of Chicago Medical Center, MC 4076, 5841 South Maryland Avenue, 60637 Chicago, IL, USA |
| |
Abstract: | Patients with ulcerative colitis have traditionally relied on sulfasalazine, mesalamine, and corticosteroids as the mainstay
of medical therapy. Steroid-refractory, -dependent, or -intolerant patients have resorted to agents such as cyclosporine for
short-term efficacy and 6-mercaptopurine or azathioprine for long-term efficacy. The next generation of evolving therapies
includes many novel agents that target various aspects of the human immune response. Therapies that block the production or
action of tumor necrosis factor have received much interest in inflammatory bowel disease. Treatments currently under study
include interleukins, interferons, T-cell selective antibodies, molecules involved in cellular trafficking and signaling,
mucosal healing or growth factors, and novel steroid agents. Other “less traditional” therapies, including probiotics, heparins,
and anti–gastric ulcer remedies, challenge our understanding of the pathogenesis of ulcerative colitis and may provide further
insights into future therapies. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|